Patents by Inventor Philip Kym

Philip Kym has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Publication number: 20080064717
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R3, X, Q, Z, A, 9, m, and n are defined herein Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: May 17, 2007
    Publication date: March 13, 2008
    Inventors: Rajesh Iyengar, Gang Zhao, Jennifer Freeman, Ju Gao, Andrew Judd, Philip Kym, John Lynch, Mathew Mulhern, Andrew Souers
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Publication number: 20080015227
    Abstract: The present invention relates to compounds of formula (I). wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: May 17, 2007
    Publication date: January 17, 2008
    Inventors: Philip Kym, Gang Zhao
  • Novel glucocorticoid receptor ligands for the treatment of metabolic disorders
    Publication number: 20070027117
    Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 1, 2007
    Inventors: Richard Bishop, Russell Cink, Bradley Gates, Lars Hagberg, Peer Jacobsen, Philip Kym, Chunqiu Lai, Marvin Leanna, James Link, Steven Richards, Noah Tu, Tom von Geldern
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Publication number: 20060287356
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 21, 2006
    Inventors: Rajesh Iyengar, Andrew Judd, Gang Zhao, Philip Kym, Hing Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard Clark, Ernst Frevert, Barbara Cool, Tianyuan Zhang, Robert Keyes, Todd Hansen, Zhili Xin
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050277638
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 15, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050209274
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 22, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187387
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 25, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187279
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: August 25, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137187
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137243
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Anil Vasudevan, Dariusz Wodka
  • Thienopyridones as AMPK activators for the treatment of diabetes and obesity
    Publication number: 20050038068
    Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
    Type: Application
    Filed: May 17, 2004
    Publication date: February 17, 2005
    Inventors: Rajesh Iyengar, Andrew Judd, Gang Zhao, Philip Kym, Hing Sham, Yugui Gu, Gang Liu, Mei Liu, Hongyu Zhao, Richard Clark, Ernst Frevert, Barbara Cool, Tianyuan Zhang, Robert Keyes, Todd Hansen, Zhili Xin